Search research articles
Contact Us
Filters
Showing results (81-90 of 176) with videos related to
Page
of 18
Sort By:
The Lancet. Neurology
|
March 31, 2012
Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Färkkilä, Hans-Christoph Diener, Gilles Géraud, et al.
Neuropeptides
|
October 30, 2009
Glyceroltrinitrate facilitates stimulated CGRP release but not gene expression of CGRP or its receptor components in rat trigeminal ganglia
Mirjam Eberhardt, Lars Neeb, Eva-Maria Vogel, et al.
European Journal of Neurology
|
June 18, 2026
Efficacy, IHS Guideline Adherence, and Methodological Quality of Noninvasive Neuromodulation Clinical Trials in Migraine and Cluster Headache: A Systematic Review
Javiera Canales-Rodríguez, Cornelius Angerhöfer, Edoardo Caronna, et al.
Lancet (London, England)
|
October 27, 2018
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter, Peter J Goadsby, Michel Lanteri-Minet, et al.
The Journal of Headache and Pain
|
January 9, 2025
Consistency between headache diagnoses and ICHD-3 criteria across different levels of care
Lucas Hendrik Overeem, Marlene Ulrich, Mira Pauline Fitzek, et al.
The Journal of Headache and Pain
|
April 17, 2021
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
Egilius L H Spierings, Mikko Kärppä, Xiaoping Ning, et al.
Cephalalgia : an International Journal of Headache
|
September 23, 2015
Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study
Charly Gaul, Hans-Christoph Diener, Nicholas Silver, et al.
Current Medical Research and Opinion
|
April 8, 2022
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
Patricia Pozo-Rosich, Holland C Detke, Shufang Wang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 6, 2021
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: results from the LIBERTY study
Michel Lanteri-Minet, Peter J Goadsby, Uwe Reuter, et al.
The Journal of Headache and Pain
|
June 2, 2024
Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry
Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 176) with videos related to
Sort By:
Page
of 18
The Lancet. Neurology
|
March 31, 2012
Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Färkkilä, Hans-Christoph Diener, Gilles Géraud, et al.
Neuropeptides
|
October 30, 2009
Glyceroltrinitrate facilitates stimulated CGRP release but not gene expression of CGRP or its receptor components in rat trigeminal ganglia
Mirjam Eberhardt, Lars Neeb, Eva-Maria Vogel, et al.
European Journal of Neurology
|
June 18, 2026
Efficacy, IHS Guideline Adherence, and Methodological Quality of Noninvasive Neuromodulation Clinical Trials in Migraine and Cluster Headache: A Systematic Review
Javiera Canales-Rodríguez, Cornelius Angerhöfer, Edoardo Caronna, et al.
Lancet (London, England)
|
October 27, 2018
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter, Peter J Goadsby, Michel Lanteri-Minet, et al.
The Journal of Headache and Pain
|
January 9, 2025
Consistency between headache diagnoses and ICHD-3 criteria across different levels of care
Lucas Hendrik Overeem, Marlene Ulrich, Mira Pauline Fitzek, et al.
The Journal of Headache and Pain
|
April 17, 2021
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
Egilius L H Spierings, Mikko Kärppä, Xiaoping Ning, et al.
Cephalalgia : an International Journal of Headache
|
September 23, 2015
Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study
Charly Gaul, Hans-Christoph Diener, Nicholas Silver, et al.
Current Medical Research and Opinion
|
April 8, 2022
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
Patricia Pozo-Rosich, Holland C Detke, Shufang Wang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 6, 2021
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: results from the LIBERTY study
Michel Lanteri-Minet, Peter J Goadsby, Uwe Reuter, et al.
The Journal of Headache and Pain
|
June 2, 2024
Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry
Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, et al.
Page
of 18